摘要
骨质疏松症作为一种严重影响人类生命健康的疾病,其危险因素及诊断依据是做好防治的关键,随着骨质疏松症发病机理研究的逐步深入,各类新型药物也层出不穷,因此,如何选择适合患者的临床药物变的越来越关键。本研究在回顾骨质疏松症最新的流行现状、诊断标准及高危因素的基础上,着重探讨了骨转换生物标志物(BTMs)及各类新型药物在骨质疏松症诊断和治疗中的优劣势,为临床治疗骨质疏松症奠定基础。
Osteoporosis,as a serious disease that affects human life and health,its risk factors and diagnosis basis are the key to prevention and treatment.With the development of the research on the pathogenesis of osteoporosis,many kinds of new drugs are emerging.Therefore,how to choose the appropriate clinical drugs for patients becomes more and more important.Based on the review of the latest epidemic status,diagnostic criteria and high-risk factors of osteoporosis,this study focused on the advantages and disadvantages of bone turnover markers(BTMs)and various new drugs in the diagnosis and treatment of osteoporosis,so as to lay the foundation for clinical treatment of osteoporosis.
作者
胡俊
陈飞
杨盼盼
沈云峰
HU Jun;CHEN Fei;YANG Panpan(Department Seven of Orthopaedics,Hongdu Hospital of Traditional Chinese Medicine Affiliated to Jiangxi University of Traditional Chinese Medicine,Nanchang 330000,China)
出处
《中国实用医药》
2020年第17期193-195,共3页
China Practical Medicine
